| |
|
|
|
|
|
 |
| |
|
¿°»êÆä´Ò¿¡ÇÁ¸°ÁÖ PHENYLEPHRINE.GNA VIAL.[Phenylephrine HCl]
|
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ(52)
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[E11980011]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml/º´(2007.03.01)(ÇöÀç¾à°¡)
\1,098 ¿ø/1ml/º´(2001.11.15)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»ö Åõ¸íÇÑ ¾×ÀÌ µç ¹ÙÀÌ¾Ë [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1VIAL |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¸¶ÃëÁßÀÇ Ç÷¾ÐÁ¶Àý°ú ô¼ö¸¶Ãë, ÈíÀÔ¸¶À§ÁßÀÇ ÀûÁ¤ ¼öÁØÀÇ Ç÷¾ÐÀ¯Áö¿Í ¼îÅ©, ¼îÅ©¾ç »óÅÂ, ¾à¹°¿ø¼º ÀúÇ÷¾Ð ¶Ç´Â °ú¹Î¹ÝÀÀ½ÃÀÇ Ç÷°ü½ÇÁ¶ Ä¡·á¸¦ À§ÇØ »ç¿ëµÇ¸ç, ¹ßÀÛ¼º »ó½É½Ç¼º ºó¸ÆÀÇ Ä¡·á, ô¼ö¸¶Ãë ½Ã°£ÀÇ ¿¬ÀåÀ» À§ÇØ ºÎºÐ¸¶Ãë½ÃÀÇ Ç÷°ü¼öÃàÁ¦·Î »ç¿ëÇÑ´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
ÀϹÝÀûÀ¸·Î ÇÇÇÏÁÖ»ç, ±ÙÀ°³»ÁÖ»ç, ¼¼È÷ Á¤¸Æ³»ÁÖ»ç ¶Ç´Â Èñ¼®¿ë¾×À¸·Î ÇÏ¿© Áö¼ÓÀûÀ¸·Î Á÷Á¢ Á¤¸ÆÁÖ»çÇÑ´Ù. ¹ßÀÛ¼º »ó½É½Ç¼º ºó¸Æ ȯÀÚ¿Í ÀÀ±ÞȯÀÚÀÇ °æ¿ì ÀÇ»çÀÇ Áö½Ã°¡ ÀÖÀ¸¸é Á÷Á¢ Á¤¸ÆÁÖ»çÇÑ´Ù. ¿ë·®Àº Ç÷¾ÐÀÇ ¹ÝÀÀ¿¡ µû¶ó Á¶ÀýµÇ¾î¾ß ÇÑ´Ù.
|
¿ë ·® °è »ê
|
|
ÇÊ¿ä ¿ë·®
|
Æä´Ò·¹ÇÁ¸°¿°»ê¿°ÁÖ»ç1%ÀÇ ¿ë·®
|
|
10mg
|
1ml
|
|
5mg
|
0.5ml
|
|
1mg
|
0.1ml
|
°£ÇæÀû Á¤¸ÆÁÖ»ç½Ã ÆíÀǸ¦ À§ÇØ Æä´Ò·¹ÇÁ¸°¿°»ê¿° 1%ÁÖ»ç¾× 1¹Ð¸®¸®Å͸¦ ÁÖ»ç¿ë¼ö 9¹Ð¸®¸®ÅÍ¿¡ ¼¯¾î¼ 0.1% ¿ë¾×À¸·Î Èñ¼®ÇÑ´Ù.
|
¿ë ·® °è »ê
|
|
ÇÊ¿ä ¿ë·®
|
Æä´Ò·¹ÇÁ¸°¿°»ê¿°ÁÖ»ç1%ÀÇ ¿ë·®
|
|
0.1mg
|
0.1ml
|
|
0.2mg
|
0.2ml
|
|
0.5mg
|
0.5ml
|
1. ÁߵÀÇ ÀúÇ÷¾Ð
1) ÇÇÇϳ» ¶Ç´Â ±ÙÀ°ÁÖ»ç : »ó¿ë·®Àº 2-5mgÀ̸ç 1-10mg ¹üÀ§³»¿¡¼ ÁÖ»çÇÑ´Ù.
ÃÊȸ·®Àº 5mgÀ» ³ÑÁö ¾Ê¾Æ¾ß ÇÑ´Ù.
2) Á¤¸ÆÁÖ»ç : »ó¿ë·®Àº 0.2mg 0.1-0.5mg ¹üÀ§¿¡¼ ÁÖ»çÇÑ´Ù. ÃʱⷮÀº
0.5mgÀ» ³ÑÁö ¾Ê¾Æ¾ß ÇÑ´Ù.
¹Ýº¹Åõ¿©½Ã 10-15ºÐ À̳»¿¡ ÀçÁÖÀԵǾ ¾ÈµÈ´Ù. 5mgÀÇ ±ÙÀ°³»ÁÖ»ç½Ã
¿ë·®Àº 1-2½Ã°£µ¿¾È Ç÷¾ÐÀ» »ó½Â½ÃŲ´Ù. 0.5mgÀÇ Á¤¸ÆÁÖ»ç½Ã ¿ë·®Àº ¾à
15ºÐ µ¿¾È Ç÷¾ÐÀ» »ó½Â½ÃŲ´Ù.
2. ½É°¢ÇÑ ÀúÇ÷¾Ð°ú ¼îÅ©-¾à¹°¿ø¼º ÀúÇ÷¾Ð Æ÷ÇÔ
Ç÷¾×·® ºÎÁ·Àº Ç÷°ü¼öÃàÁ¦¸¦ Åõ¿©Çϱâ ÀÌÀü¿¡ ÃæºÐÈ÷ ±³Á¤µÇ¾î¾ß¸¸ ÇÑ´Ù.
±×·¯³ª, ÀÀ±Þóġ·Î¼ ´ë³ú ¶Ç´Â °ü»óµ¿¸ÆÇãÇ÷ ¿¹¹æÀ» À§ÇØ ´ëµ¿¸Æ³»
Ç÷¾ÐÀÌ À¯ÁöµÇ¾î¾ß¸¸ ÇÒ °æ¿ì Ç÷¾×·® º¸Ãæ°ú ÇÔ²² ¶Ç´Â ±× ÀÌÀü¿¡ Åõ¿©ÇÒ
¼ö ÀÖ´Ù.
±³°¨½Å°æ ¹× ½Å°æÀýÂ÷´ÜÁ¦, ¶ó¿ìº¼ÇǾÆ(rauwolfia) ¾ËÄ®·ÎÀÌµå ¹× º£¶óÆ®·ë
(veratrum) ¾ËÄ®·ÎÀÌµå ¶Ç´Â Æä³ëÄ¡¾ÆÁø°è ½Å°æ¾ÈÁ¤Á¦ µîÀÇ °ú·®Åõ¿© ¶Ç´Â
ƯÀÌüÁú·Î ÀÎÇÑ ÀúÇ÷¾ÐÀ̳ª ½É°¢ÇÑ ¼îÅ©°¡ ÀϾ ¼ö ÀÖ´Ù.
¼ö¼úÀü óġ·Î¼ Æä³ëÄ¡¾ÆÁø À¯µµÃ¼¸¦ Åõ¿©¹Þ´Â ȯÀڴ ƯÈ÷ ÀúÇ÷¾ÐÀ̳ª
½É°¢ÇÑ ¼îÅ© ¹ÝÀÀ¿¡ ¹Î°¨Çϸç, ÀÌ·± °æ¿ì ÀÌ Á¦Á¦°¡ Ç÷¾Ðȸº¹À» À§ÇÑ
°ü¸®¿¡ ¸Å¿ì ÀûÀýÇÏ´Ù.
Áö¼ÓÀûÀ̰ųª Àß Ä¡·áµÇÁö ¾Ê´Â ½ÉÇÑ ÀúÇ÷¾Ð ¶Ç´Â ¼îũȯÀÚ¿¡¼´Â ÀÌ ¾àÀÇ
Ãʱⷮ ¹× À¯Áö·®À» ÀûÀýÈ÷ Áõ·®ÇÏ¿© »ç¿ëÇÑ´Ù.
°·ÂÇÑ ¸»Ãʱ³°¨½Å°æÂ÷´ÜÁ¦, Ŭ·Î¸£ÇÁ·Î¸¶Áø, ģũ·Ò¼º¼¼Æ÷Á¾ ÀýÁ¦¼ú¿¡
ÀÇÇÑ ÀúÇ÷¾Ð µîµµ º¸´Ù °ÇÑ Ä¡·á¸¦ ÇÊ¿ä·Î ÇÑ´Ù.
Á¡Àû ÁÖ»ç : Æä´Ò·¹ÇÁ¸°¿°»ê¿°À¸·Î 10mg(1%¿ë¾×À¸·Î¼ 1ml)À» 500mlÀÇ Æ÷µµ´ç
ÁÖ»ç¾× ¶Ç´Â »ý¸®½Ä¿°ÁÖ»ç¾×À¸·Î Èñ¼®ÇÑ´Ù (1:50,000 ¿ë¾×). Ç÷¾ÐÀ»
½Å¼ÓÈ÷ ¿Ã¸®±â À§Çؼ´Â ÃʱⷮÀ» 100-180mcg/ºÐ(20Àû/ml¸¦ ±âÃÊ·Î ÇÒ ¶§
100-180Àû/ºÐ)À¸·Î ÇÑ´Ù. Ç÷¾ÐÀÌ ¾ÈÁ¤ÈµÇ¸é À¯Áö·®Àº 40-60mcg/ºÐ
(20Àû/ml¸¦ ±âÃÊ·Î ÇÒ ¶§ 40-60Àû/ºÐ)À¸·Î Çϸé ÃæºÐÇÏ´Ù. Á¡Àû±âÀÇ
Å©±â¿¡ µû¶ó ml´ç Á¡Àû¼ö°¡ ´Ù¸£´Ù¸é ÀÌ¿¡ µû¶ó Á¶Á¤µÇ¾î¾ß ÇÑ´Ù.
¸¸ÀÏ ½Å¼ÓÇÑ ÃÖÃÊÀÇ ¹ÝÀÀÀÌ ÀϾÁö ¾Ê´Â´Ù¸é Æä´Ò¿¡ÇÁ¸° Ãß°¡·®(10mg
¶Ç´Â ±× ÀÌ»ó)À» Á¡Àûº´¿¡ Ãß°¡ÇÑ´Ù. ±×¸®°í ³ª¼ À¯Ãâ·®ÀÇ ºñÀ²Àº
¿øÇÏ´Â Ç÷¾ÐÄ¡°¡ µÉ ¶§±îÁö Á¶ÀýÇÑ´Ù. ¶§·Î ÁßÁÖ¼®»ê³ë¸£¿¡Çdz×ÇÁ¸° °°Àº
º¸´Ù °·ÂÇÑ Ç÷°ü¼öÃàÁ¦°¡ ÇÊ¿äÇϱ⵵ ÇÏ´Ù.
°íÇ÷¾ÐÀÌ µÇÁö ¾Êµµ·Ï ÁÖÀÇÇÏ¿©¾ß ÇÑ´Ù. Ç÷¾ÐÀº ÀÚÁÖ Ã¼Å©µÇ¾î¾ß ÇÑ´Ù.
µÎÅëÀ̳ª ¼¸ÆÀº °íÇ÷¾ÐÀ» ³ªÅ¸³»´Â °ÍÀÌ´Ù. ºÎÁ¤¸ÆÀº µå¹°´Ù.
3. ô¼ö¸¶Ãë-ÀúÇ÷¾Ð
ÀϹÝÀûÀÎ Æä´Ò¿¡ÇÁ¸°ÀÇ ºñ°æ±¸Àû »ç¿ëÀº ô¼ö¸¶Ãë½Ã ÀúÇ÷¾ÐÀÇ ¿¹¹æ°ú Ä¡·á¿¡ ÃßõµÈ´Ù. ô¼ö¸¶Ãë ÁÖ»ç 3-4ºÐÀü¿¡ ÇÇÇϳ» ¶Ç´Â ±ÙÀ°³»ÁÖ»çÇÏ´Â °ÍÀÌ ÁÁ´Ù. °íÀ§ ô¼ö¸¶Ãë½ÃÀÇ ÃÑ Çʿ䷮Àº º¸Åë 3mgÀ̰í, ÀúÀ§ ¸¶Ãë½Ã¿¡´Â 2mgÀÌ´Ù. ô¼ö¸¶ÃëÁß ÀúÇ÷¾Ð ÀÀ±Þ½Ã´Â Æä´Ò¿¡ÇÁ¸°À» Á¤ÁÖÇϸç Ãʱⷮ 0.2mgÀÌ´Ù. Ãß°¡¿ë·®Àº ±×Àü¿¡ Åõ¿©ÇÑ ¿ë·®¿¡¼ 0.1-0.2mg ÀÌ»óÀ» ÃʰúÇØ¼´Â ¾ÈµÈ´Ù. 1ȸ Åõ¿©·® 0.5 ¹Ð¸®±×·¥À» ³Ñ¾î¼´Â ¾ÈµÈ´Ù.
¾î¸°ÀÌÀÇ Ã´¼ö¸¶Ãë½Ã ÀúÇ÷¾ÐÀ» ±Øº¹Çϱâ À§Çؼ´Â üÁßÀ» ±âÁØÀ¸·Î 0.5-1 ¹Ð¸®±×·¥/25ÆÄ¿îµå(11.34ų·Î±×·¥)¸¦ ÇÇÇÏ ¶Ç´Â ±ÙÀ°³» Åõ¿©ÇÏ´Â °ÍÀÌ ÃßõµÈ´Ù.
4. ô¼ö¸¶ÃëÀÇ ¿¬Á¤
¸¶Ãë¿ë¾×¿¡ Æä´Ò·¹ÇÁ¸°¿°»ê¿° 2-5¹Ð¸®±×·¥À» ÷°¡ÇÏ¸é ±¸¿ª, ±¸Åä, Ç÷¾ÐºÎÁ¶ µîÀÇ ÇÕº´Áõ ¹ß»ý ¾øÀÌ ¿îµ¿¼º Â÷´ÜÀÇ Áö¼ÓÀ» ¾à 50%Á¤µµ Áõ°¡½Ãų¼ö ÀÖ´Ù.
5. ±¹¼Ò¸¶Ãë½Ã Ç÷°ü¼öÃàÁ¦
Ç÷°ü¼öÃàÁ¦·Î »ç¿ëµÉ ¶§ Àû¿ëµÇ´Â ¿¡Çdz×ÇÁ¸°ÀÇ ³óµµÀÇ ¾à 10¹è Á¤µµ°¡ ÃßõµÈ´Ù. ÃÖÀû ³óµµ´Â 1:20.000ÀÌ´Ù(¸Å 20 ¹Ð¸®¸®ÅÍÀÇ ±¹¼Ò¸¶Ãë¿ë¾×¿¡ Æä´Ò·¹ÇÁ¸°¿°»ê¿° 1¹Ð¸®±×·¥À» °¡ÇÏ¿© ¸¸µç´Ù.) 2¹Ð¸®±×·¥ ÀÌ»ó ÁÖÂ÷½Ã¿¡´Â ½Â¾Ð¹ÝÀÀÀÌ ÀϾ ¼ö ÀÖ´Ù.
6. ¹ßÀÛ¼º »ó½É½Ç¼º ºó¸Æ
½Å¼ÓÇÑ Á¤¸Æ³»ÁÖ»ç(20-30ÃÊ À̳»)°¡ ¿ä±¸µÈ´Ù. ÃÖÃʿ뷮Àº 0.5¹Ð¸®±×·¥À» ³Ñ¾î¼´Â ¾ÈµÇ¸ç, Ãß°¡·®Àº ÃÖÃÊÀÇ Ç÷¾Ð¹ÝÀÀ¿¡ µû¶ó °áÁ¤Çϰí ÀÌÀü·®º¸´Ù 0.1-0.2 ¹Ð¸®±×·¥À» ³ÑÁö ¾Ê¾Æ¾ß Çϸç 1¹Ð¸®±×·¥À» ÃʰúÇØ¼´Â ¾ÈµÈ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
ÀÌ ¾àÀº ½É°¢ÇÑ °íÇ÷¾Ð, ½É½Ç¼º ºó¸Æ ȯÀÚ¿Í ÀÌ ¾à¿¡ °ú¹Î¼ºÀÌ Àִ ȯÀÚ´Â
»ç¿ëÇØ¼´Â ¾ÈµÈ´Ù.
|
| ½ÅÁßÅõ¿© |
ÀÌ ¾àÀº °í·ÉÀÇ È¯ÀÚ, °©»ó¼±±â´ÉÇ×Áø ȯÀÚ, ¼¸Æ ȯÀÚ, ºÎºÐÀû ½ÉÂ÷´Ü
ȯÀÚ, ºÎºÐÀû ½ÉÂ÷´Ü ȯÀÚ, ½É±Ù¼º Áúȯ ¶Ç´Â ½É°¢ÇÑ Á×»ó µ¿¸Æ°æÈÁõ
ȯÀÚ´Â ÁÖÀÇÇÏ¿© Åõ¿©ÇÏ¿©¾ß ÇÑ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
µÎÅë, ¹Ý»ç¼º ¼¸Æ, ÈïºÐ, ºÒ¾È ±×¸®°í µå¹°°Ô ºÎÁ¤¸ÆÀÌ ÀϾ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) Ç÷¾Ð»ó½ÂÁ¦, ƯÈ÷ ¸ÞŸ¶ó¹Ì³îÀº ÇÒ·Îź ¸¶ÃëÁß ½É°¢ÇÑ ½ÉÀ强 ºÎÁ¤¸ÆÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀǸ¦ ÇØ¼ »ç¿ëÇϰųª »ç¿ëÇÏÁö ¾Ê´Â °ÍÀÌ ÁÁ´Ù.
2) MAOÁ¦ÇØÁ¦ : ±³°¨½Å°æÈïºÐ ½Â¾Ð¾Æ¹Î·ùÀÇ ½Â¾ÐÈ¿°ú´Â MAOÁ¦ÇØÁ¦¸¦ Åõ¿©¹Þ°í
Àִ ȯÀÚ¿¡°Ô¼ ÇöÀúÈ÷ »ó½ÂµÈ´Ù. ±×·¡¼ ÀÌ·¯ÇÑ È¯Àڵ鿡°Ô¼
½Â¾ÐÄ¡·á¸¦ ÇÒ ¶§ ÃÊȸ·®Àº ¼Ò·®À̾î¾ß Çϸç ÁÖÀǸ¦ ¿äÇÑ´Ù. ¾Æµå·¹³¯
¸°¼º ¾à¹°ÀÇ ½Â¾Ð¹ÝÀÀ ¶ÇÇÑ »ïȯ°è Ç׿ì¿ïÁ¦¿¡ ÀÇÇØ¼µµ »ó½ÂµÈ´Ù.
3) »ïȯ°è Ç׿ì¿ïÁ¦¿¡ ÀÇÇØ¼µµ ±³°¨½Å°æ°è ¾à¹°ÀÇ ½Â¾ÐÀÛ¿ëÀÌ Áõ°µÉ ¼ö
ÀÖ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(ÀÓ»ó ½ÃÇè¿¡¼ À§Ç輺 º¸°íµÊ. -Briggs G, et al. Drugs in Pregnancy and Lactation 7th edit. )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Phenylephrine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Phenylephrine produces its ophthalmic and systemic actions by acting on alpha 1 adrenergic receptors in the pupillary dilator muscle and the vascular smooth musle, resulting in contraction of the dilator muscle and contraction of the smooth muscle in the arterioles of the conjunctiva and peripheral vasoconstriction. Phenylephrine decreases nasal congestion by acting on alpha 1 adrenergic receptors in the arterioles of the nasal mucosa to produce constriction.
|
| Pharmacology |
Phenylephrine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Phenylephrine is a powerful vasoconstrictor. It is used as a mydriatic, nasal decongestant, and cardiotonic agent. Phenylephrine is a postsynaptic alpha-receptor stimulant with little effect on the beta receptors of the heart. Parenteral administration of Phenylephrine causes a rise in systolic and diastolic pressures, cardiac output is slightly decreased and peripheral resistance is considerably increased, most vascular beds are constricted; renal, splanchnic, cutaneous, and limb blood flows are reduced but coronary blood flow is increased. Pulmonary vessels are constricted, and pulmonary arterial pressure is raised. This alpha receptor sympathetic agonist is also used locally because its vasoconstrictor and mydriatic action.
|
| Metabolism |
Phenylephrine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A)
|
| Protein Binding |
Phenylephrine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 95% binding-plasma proteins
|
| Half-life |
Phenylephrine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2.1 to 3.4 hours
|
| Absorption |
Phenylephrine¿¡ ´ëÇÑ Absorption Á¤º¸ Reduced bioavailability (compared to pseudoephedrine) following oral administration due to significant first-pass metabolism.
|
| Pharmacokinetics |
Phenylephrine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£
- ±ÙÀ°ÁÖ»ç, ÇÇÇÏÁÖ»ç : 10~15ºÐ À̳»
- Á¤¸ÆÁÖ»ç : Áï½Ã
- È¿°úÁö¼Ó½Ã°£
- ±ÙÀ°ÁÖ»ç : 30ºÐ ~ 2½Ã°£
- Á¤¸ÆÁÖ»ç : 15~30ºÐ
- ÇÇÇÏÁÖ»ç : 1½Ã°£
- ´ë»ç : Phenolic Æ÷ÇÕü·Î ´ë»çµÊ. Monoamine oxidase¿¡ ÀÇÇØ °£°ú Àå¿¡¼ ´ë»çµÊ.
- ¹Ý°¨±â : 2.5 ½Ã°£
- ¼Ò½Ç : ½Å¹è¼³ (90%)
|
| Biotransformation |
Phenylephrine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Oral phenylephrine is extensively metabolised by monoamine oxidase, an enzyme which is present in the stomach and liver.
|
| Toxicity |
Phenylephrine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Phenylephrine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alseroxylon Increased arterial pressureIsocarboxazid Increased arterial pressureDeserpidine Increased arterial pressureGuanethidine The agent decreases the effect of guanethidineRasagiline Increased arterial pressureMethyldopa Increased arterial pressureMidodrine Increased arterial pressurePargyline Increased arterial pressurePhenelzine Increased arterial pressureReserpine Increased arterial pressureTranylcypromine Increased arterial pressureOxytocin Possible marked increase of arterial pressureMethylergonovine Possible marked increase of arterial pressureLinezolid Possible increase of arterial pressureErgonovine Possible marked increase of arterial pressureTrimipramine The tricyclic increases the sympathomimetic effectProtriptyline The tricyclic increases the sympathomimetic effectNortriptyline The tricyclic increases the sympathomimetic effectClomipramine The tricyclic increases the sympathomimetic effectAmitriptyline The tricyclic increases the sympathomimetic effectAmoxapine The tricyclic increases the sympathomimetic effectDesipramine The tricyclic increases the sympathomimetic effectDoxepin The tricyclic increases the sympathomimetic effectImipramine The tricyclic increases the sympathomimetic effectMoclobemide Moclobemide increases the sympathomimetic effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Phenylephrine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.
|
| Drug Target |
[Drug Target]
|
| Description |
Phenylephrine¿¡ ´ëÇÑ Description Á¤º¸ An alpha-adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. [PubChem]
|
| Dosage Form |
Phenylephrine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntramuscularLiquid IntravenousLiquid OphthalmicOintment TopicalSolution IntravenousSolution / drops OphthalmicStrip OralTablet Oral
|
| Drug Category |
Phenylephrine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic alpha-AgonistsCardiotonic AgentsMydriaticsNasal DecongestantsSympathomimeticsVasoconstrictor Agents
|
| Smiles String Canonical |
Phenylephrine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CNCC(O)C1=CC(O)=CC=C1
|
| Smiles String Isomeric |
Phenylephrine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CNC[C@H](O)C1=CC(O)=CC=C1
|
| InChI Identifier |
Phenylephrine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
|
| Chemical IUPAC Name |
Phenylephrine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3-[(1R)-1-hydroxy-2-methylaminoethyl]phenol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-07-28
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|